To read the full story, subscribe or sign in.

STATute of limitations? Time running out for ‘undruggable’ SH2 as Recludix bags $60M series A

Nov. 15, 2021

Recludix Pharma Inc. launched with a $60 million series A round to target Src homology 2 (SH2) domains, and the new money will get the San Diego-based firm to reach the IND-enabling stage, CEO Nancy Whiting told BioWorld.

BioWorld Financings Cancer Inflammatory Series A

Today's news in brief

BioWorld

BioWorld briefs for April 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 10, 2025.

Approved label with medical icons, professional

FDA clears path for Boston Sci’s Bolt IVL to challenge J&J’s Shockwave

BioWorld MedTech

Boston Scientific Corp.’s up to $664 million acquisition of Bolt Medical Inc. closed just days after Bolt secured U.S. FDA 520(k) clearance for its intravascular...

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Remegen’s lupus drug surfaces with phase III myasthenia gravis data

BioWorld

Remegen Co. Ltd. emerged as a surprise challenger in the generalized myasthenia gravis space, unveiling positive phase III data of its China-approved lupus drug,...